Cite
FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
MLA
Bach, Peter B., et al. “FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.” JAMA: Journal of the American Medical Association, vol. 318, no. 19, Nov. 2017, pp. 1861–62. EBSCOhost, https://doi.org/10.1001/jama.2017.15218.
APA
Bach, P. B., Giralt, S. A., & Saltz, L. B. (2017). FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. JAMA: Journal of the American Medical Association, 318(19), 1861–1862. https://doi.org/10.1001/jama.2017.15218
Chicago
Bach, Peter B., Sergio A. Giralt, and Leonard B. Saltz. 2017. “FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.” JAMA: Journal of the American Medical Association 318 (19): 1861–62. doi:10.1001/jama.2017.15218.